Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.

NPJ breast cancer·2026
Same author

BRAF<sup>V600E</sup> patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data.

Journal of experimental & clinical cancer research : CR·2026
Same author

Proteomic profiling of colorectal liver metastases reveals histopathological response-specific molecular signatures of chemotherapy efficacy.

Journal of translational medicine·2026
Same author

Cancer evolution and multi-omic profile of relapsed colorectal liver metastases after treatment.

Genome medicine·2026
Same author

Epigenetic dysregulation of IRF9 drives excessive interferon signaling in COPD.

EMBO molecular medicine·2026
Same author

Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer.

Science signaling·2025

Related Experiment Video

Updated: May 24, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies.

Arne Warth1, Roland Penzel, Regine Brandt

  • 1Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 220/221, 69120, Heidelberg, Germany.

Virchows Archiv : an International Journal of Pathology
|March 16, 2012
PubMed
Summary
This summary is machine-generated.

Accurate EGFR mutation analysis in non-small cell lung cancer (NSCLC) biopsies requires a minimum tumor cell concentration. This study defines the threshold for reliable diagnostics and develops an algorithm to improve EGFR mutation testing in NSCLC patients.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Related Experiment Videos

Last Updated: May 24, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
11:11

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing

Published on: August 24, 2017

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • EGFR mutations in pulmonary adenocarcinoma predict response to tyrosine kinase inhibitors.
  • Accurate EGFR mutational status is crucial for non-small cell lung cancer (NSCLC) treatment and prognosis.
  • NSCLC biopsy specimens often have insufficient tumor content for reliable molecular analysis.

Purpose of the Study:

  • To determine the minimal tumor cell concentration for reliable EGFR mutation detection in NSCLC biopsies.
  • To develop and validate an algorithm for routine EGFR mutation analysis on biopsy material using Sanger sequencing.

Main Methods:

  • Serial dilution of DNA from EGFR-mutated NSCLC with non-tumor DNA.
  • Determination of tumor and non-tumor cell counts to calculate tumor cell concentration.
  • Application of a developed algorithm to 461 diagnostic NSCLC biopsy cases.

Main Results:

  • A minimum tumor cell concentration of 30% (counted) or 40% (histologically estimated) is required for reliable EGFR mutation detection.
  • The developed algorithm improved the reliability of EGFR mutation analyses in biopsy specimens to 80%.
  • 20% of cases still required re-biopsy recommendations due to insufficient tumor content.

Conclusions:

  • Establishing a minimal tumor cell concentration threshold is essential for accurate EGFR mutation diagnostics in NSCLC biopsies.
  • An evidence-based algorithm significantly enhances the reliability of EGFR mutation testing on limited biopsy material.
  • Optimized diagnostic strategies, including potential re-biopsies, are critical for effective targeted therapy selection in NSCLC.